57757-74-1

Basic information

• Product Name: Benzoic acid, 4-(hydroxymethyl)-2-methoxy-, methyl ester
• CAS NO: 57757-74-1
• Molecular Formula: C10H12O4
• Molecular Weight: 196.203
• Mol File: 57757-74-1.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 4-(hydroxymethyl)-2-methoxy-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 4-(hydroxymethyl)-2-methoxy-, methyl ester(57757-74-1)
• EPA Substance Registry System: Benzoic acid, 4-(hydroxymethyl)-2-methoxy-, methyl ester(57757-74-1)

Safety Data

• Hazardous Substances Data: 57757-74-1(Hazardous Substances Data)

Upstream product

• 50-85-1 2-hydroxy-p-toluic acid 
• 189094-76-6 methyl 4-[(acetyloxy)methyl]-2-methoxybenzoate 
• 4670-56-8 methyl 2-hydroxy-4-methylbenzoate 
• 81245-24-1 methyl 4-methyl-2-methoxybenzoate 
• 74733-27-0 methyl 4-bromomethyl-2-methoxybenzoate 
• 124-38-9 carbon dioxide 
• 52520-37-3 (3-Methoxybenzyl alcohol)chromium Tricarbonyl 
• 186581-53-3 diazomethane 
• 158089-31-7 4-(hydroxymethyl)-2-methoxybenzoic acid 
• 6971-51-3 3-methoxybenzyl alcohol 

Downstream Products

• 55204-14-3 methyl 4-formyl-2-methoxybenzoate 
• 1351169-42-0 methyl 2-(3-{2-[2-(2-{2-[(S)-2-((2S,3R)-3-{[(9H-fluoren-9-yl)methoxy]carbonylamino}-2-hydroxy-4-phenylbutanamido)-4-methylpentanamido]ethoxy}ethoxy)ethoxy]acetamido}propoxy)-4-[(E)-3-(3,5-di-tert-butylphenyl)-3-oxoprop-1-enyl]benzoate 
• 1351169-27-1 2-[3-(2-{2-[2-(2-{(S)-2-[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanamido]-4-methylpentanamido}ethoxy)ethoxy]ethoxy}acetamido)propoxy]-4-[(E)-3-(3,5-di-tert-butylphenyl)-3-oxoprop-1-enyl]benzoic acid 
• 1351169-43-1 (S,E)-methyl 4-[3-(3,5-di-tert-butylphenyl)-3-oxoprop-1-enyl]-2-(3-{2-[2-(2-{2-[4-methyl-2-(4-phenylbutanamido)pentanamido]ethoxy}ethoxy)ethoxy]acetamido}propoxy)benzoate 
• 1351169-28-2 (S,E)-4-[3-(3,5-di-tert-butylphenyl)-3-oxoprop-1-enyl]-2-(3-{2-[2-(2-{2-[4-methyl-2-(4-phenylbutanamido)pentanamido]ethoxy}ethoxy)ethoxy]acetamido}propoxy)benzoic acid 
• 1351169-33-9 C₂₆H₃₂O₄ 
• 1351169-34-0 C₂₅H₃₁BrO₄ 
• 1351169-35-1 (E)-methyl 4-[3-(3,5-di-tert-butylphenyl)-3-oxoprop-1-enyl]-2-hydroxybenzoate 
• 1351169-36-2 (E)-methyl 2-[3-(tert-butoxycarbonylamino)propoxy]-4-[3-(3,5-di-tert-butylphenyl)-3-oxoprop-1-enyl]benzoate 
• 1351169-37-3 (E)-methyl 2-(3-aminopropoxy)-4-[3-(3,5-di-tertbutylphenyl)-3-oxoprop-1-enyl]benzoate hydrochloride 
• 1027035-76-2 methyl 4-(aminomethyl)-2-methoxybenzoate 
• 1204703-62-7 methyl 4-(azidomethyl)-2-methoxybenzoate 

Relevant articles and documents

PHARMACEUTICAL COMPOUNDS

This invention relates to compounds that inhibit or modulate the activity of Chk-1 kinase. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds.

PIPERIDINE DERIVATIVES AS HUMAN PAPILLOMA VIRUS INHIBITORS

HPV inhibitors with formula (I) where G1 represents a hydrocarbonated bond or chain possibly substituted by one or two alkyl groups, G2 represents a group (see formula Ia+Ib) or R represents a hydrogen, an alkyl, halogenoalkyl, or a prodrug radical such as carbamate, acetyl or dialkylaminomethyl, G represents a bond or a hydrocarbonated chain possibly substituted by one or two alkyls, W represents an oxygen or sulphur, R1 and R2 each represent a group chosen from among hydrogen, halogen, hydroxyl, thio, alkoxy, halogenoalkoxy, alkylthio, halogenoalkylthio, amino, monoalkylamino, dialkylamino, cycloalkyl, alkyl or halogenoalkyl, R3 represents an acid or a prodrug radical of the acid function or a bioisostere of the acid function, A represents an aryl, cycloalkyl, cycloalkenyl or a heterocycle, each possibly substituted, and B represents an aryl or a heterocycle with 6 chains, each possibly substituted, and pharmaceutically acceptable salts.

Directed regioselective lithiation of (η6-arene) chromium tricarbonyl complexes. Regioselective synthesis of anthraquinones and calamenenes

(3-Methoxybenzylalcohol)chromium tricarbonyl (10) and (7-methoxy-1-tetralol)chromium tricarbonyl (12) are selectively lithiated at the 4- and 6-positions, respectively, by treatment with n-BuLi-TMEDA. Since the directed lithiation of the corresponding chromium free arenes normally proceeds at the 2-and 8-positions, complementarily substituted arenes can be prepared by using the chromium tricarbonyl complexes. The difierent position of lithiation is explained by the relative configuration of the chromium tricarbonyl group in the (arene)Cr(CO)3 and electrostatic factors. Some anthraquinones, 31,36,42, and 7-hydroxycalamenenes, 43, have been synthesized through the stereo- and regioselective introduction of substituents by means of(η6-arene)chromium tricarbonyl complexes.